Saturday, Sept. 12, 2020 : Issue #1062

TOP STORIES - Diabetes News & Research

The Link Between Obesity and Incidence Of Dementia

Determining Which Type 1 Patients Will Experience A Partial Remission

How A Bowl of Cereal Can Help Prevent Diabetes

Letter from the Editor

When we see children who are diagnosed with type 1 diabetes to start therapy, we often are hesitant to go full bore because of the chance for a honeymoon period where their pancreas begins to produce insulin again. Although this honeymoon period is often short-lived, the risk of hypoglycemia is very high.

In the past we did not treat our older patients with type 1 the same way, as the consensus was they would likely not have the same hypoglycemic risk as children. Now, in a new series of articles that our intern Joel John, PharmD candidate FAMU College of Pharmacy, has researched, we find that this is not likely true.

Check out his article and why you need to pay attention to possible remissions for all your patients.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Newsflash: FDA Approves 2 New Dulaglutide Doses

The FDA recently approved 2 additional doses of dulaglutide (Trulicity; Eli Lilly) for the treatment of type 2 diabetes. Approval of the 3.0 mg and 4.5 mg doses of dulaglutide was based on favorable results in regard to A1C and bodyweight reduction, stemming from the phase 3 AWARD-11 clinical trial comparing the additional doses with 1.5 mg doses in individuals with type 2 diabetes. Lilly intends to offer dulaglutide 3.0 mg and 4.5 mg by late September. According to the study, both of the investigational doses led to significant reductions in A1C and weight in participants who remained on treatment throughout the trial:

4.5 mg (A1C: -1.9%; weight: -10.4 pounds)
3.0 mg (A1C: -1.7%; weight: -8.8 pounds)
1.5 mg (A1C: -1.5%; weight: -6.8 pounds)

Did You Know? How even a 1/2 glass of alcohol increases the risk of obesity:

Consuming more than half a standard alcoholic drink a day (equivalent to 7g of pure alcohol) is associated with an increased risk of obesity and metabolic syndrome in both men and women. The risk rises in proportion with alcohol intake, according to a nationwide study involving nearly 27 million adults (aged 20 years and older). The study defines one standard alcoholic drink as 14g alcohol per day, which is roughly equivalent to a small (118ml) glass of wine or a 355ml bottle of beer. WHO defines a standard alcoholic drink as 10 g of pure ethanol, with both men and women advised not to exceed two standard drinks per day. Even after accounting for potentially influential factors including age, exercise, smoking, and income, the analysis found a strong association between alcohol consumption and obesity and metabolic syndrome, which put people at higher risk of heart disease, heart attacks, and stroke if uncontrolled. Compared with non-drinkers, those who drank on average between half and one standard drink a day (7.1-14g alcohol) were around 10% more likely to have obesity and metabolic syndrome, while consuming up to two drinks a day (14.1-24g alcohol) was associated with 22% and 25% greater odds, respectively. The highest risk was seen in those who drank more than two drinks, or 24g alcohol, per day, with 34% higher odds of obesity and 42% greater odds of metabolic syndrome. The authors conclude: "Our results suggest that the risk of obesity and metabolic syndrome increases in proportion to alcohol consumption when male and female adults drink more than half a standard drink per day."

EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY SEPTEMBER 2, 2020

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Fairuz Afram, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences

Louise Brown, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy

Joel John, Pharm.D. Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Maya Palmer, PharmD. Candidate, Florida A&M University College of Pharmacy

Peter Jay Won, Pharm.D. Candidate, University of South Florida, Taneja College of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

Saturday, Sept. 12, 2020 : Issue #1062

TOP STORIES - Diabetes News & Research

Newsflash: FDA Approves 2 New Dulaglutide Doses

TOP STORIES - Diabetes News and Research

Did You Know? How even a 1/2 glass of alcohol increases the risk of obesity:

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: